Summary
This paper addresses a fundamental methodological challenge in Mendelian randomisation—the assumption of no horizontal pleiotropy—by demonstrating how this assumption is stronger when proteins, rather than distal risk factors, are the objects of causal inference. The authors introduce a mathematical framework and analytical toolkit to support MR studies of drug targets, a rapidly growing application in early-stage drug development. The work bridges genetic epidemiology and translational medicine by providing practical guidance for maximising analytical rigour in protein-targeted causal inference.
UK applicability
This methodological framework is applicable to UK-based and international genomic research programmes examining drug targets. As the UK maintains significant capacity in genetic epidemiology and pharmaceutical research, the analytical framework may inform best-practice standards for causal inference in drug development pipelines operating within or serving UK populations.
Key measures
Mathematical assumptions underpinning MR; horizontal pleiotropy assessment; statistical power in protein-based MR analyses; robustness evaluation metrics
Outcomes reported
The study introduces a mathematical framework that strengthens causal inference for Mendelian randomisation (MR) analyses when proteins are the risk factors of interest, contrasting this with MR analysis of distally-located risk factors. The framework provides analytical guidance for maximising statistical power and evaluating robustness in drug target validation studies.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.